Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
UB-312 by Vaxxinity for Parkinson's Disease: Likelihood of Approval
UB-312 is under clinical development by Vaxxinity and currently in Phase I for Parkinson's Disease. According to GlobalData, Phase I...